Patent · US Active

Composition for inhibiting CTGF expression

US12234458B2 · kind B2 · utility

0Cited by
1References
10Claims
0Family size

Assignee

Inventor

Key dates

Filing dateJan 29, 2021
Grant dateFeb 25, 2025
Priority date
Expiry dateDec 30, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/351
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A composition according to an embodiment of the present invention includes nucleic acid molecules which are capable of effectively inhibiting the expression level of connective tissue growth factor (CTGF) and collagen by RNA interference (RNAi), thereby preventing or treating a variety of fibroproliferative diseases due to overexpression of CTGF or collagen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.